Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1
Adagene Announces First Patient Dosed in Phase
1 Study of ADG138, a Novel HER2×CD3 Double-Masked Bispecific T-Cell Engager
First-in-human study will enroll patients with
HER2-positive advanced solid tumors
ADG138 design includes proprietary IgG1-based heterodimeric format
and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation
SAN
DIEGO, Calif. November 19, 2026 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage
biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient
has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based
format and Adagene’s proprietary SAFEbody® precision masking technology.
“Dosing the first patient with ADG138 is an important step in
moving our double-masked T-cell engager from preclinical research into the clinic,” said Peter Luo, Ph.D., Chairman, CEO and President
of R&D at Adagene. “Our preclinical data showed that masking both the HER2 and CD3 binding sites preserved ADG138’s antitumor
activity, including in Enhertu (DS-8201)-resistant models, while reducing cytokine release and widening the therapeutic window compared
with an unmasked T-cell engager.
“Clinical
experience with muzastotug, our masked anti-CTLA-4 SAFEbody in IgG1 format, now includes more than 250 patients dosed with high, repeated
dosing, and continuous treatment beyond two years in some patients. Together with ADG138’s robust preclinical findings, this reinforces
our confidence in extending SAFEbody technology to T-cell engagers. We look forward to evaluating ADG138’s safety and preliminary
efficacy in heavily pretreated patients who have progressed after multiple lines of therapies, including standard-of-care
and investigational HER2-directed antibody-drug conjugates.”
The
open-label Phase 1 study is designed to evaluate the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced
solid tumors and determine the recommended Phase 2 dose. Dose escalation will begin with a starting dose of 2 mg of ADG138, and subsequent
doses will be guided by emerging clinical data.
About ADG138
ADG138 is a double-masked HER2×CD3 bispecific T cell engager
designed using Adagene’s proprietary IgG-based heterodimeric format and SAFEbody® precision masking technology, which covalently
links masking peptides to both the HER2- and CD3-binding arms of the molecule. In its inactivated state, ADG138 is designed to minimally
bind HER2-expressing cancer cells and T cells; the molecule becomes activated within the tumor microenvironment and engages T cells to
selectively kill HER2-expressing tumor cells while limiting off-target toxicity.
In preclinical models, the double-masked ADG138 has achieved approximately
220-fold and greater than 1,000-fold reductions in binding to HER2 and CD3, respectively, compared to its unmasked form. Upon activation
in the tumor microenvironment, ADG138 enables highly efficient T cell-mediated tumor cell killing, driving tumor regression in both HER2-high
and HER2-low tumor models, including a model refractory and/or resistant to the Enhertu (DS-8201). ADG138 has also shown synergistic anti-tumor
activity in combination with anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies. In addition, ADG138 was tolerated at doses over 300-fold
higher than an unmasked T-cell engager, with markedly reduced cytokine release and a favorable pharmacokinetic profile, including a longer
apparent half-life and higher systemic exposure than the parental molecule.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology
company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational
biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic
collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the
vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform,
composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel
immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with
many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation
in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in
healthy tissues.
Adagene’s lead clinical program, muzastotug (ADG126), is a masked,
anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor
microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly
focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform
can be applied to a wide variety of antibody-based therapeutic modalities, including Fc-empowered antibodies, antibody-drug conjugates,
and bi/multi-specific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.
SAFEbody® is a registered trademark in the United States, China,
Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements
regarding ADG138’s potential therapeutic benefits, the intended effects of its dual-masking design, the objectives of its Phase
1 study and starting-dose strategy, and Adagene’s anticipated preclinical activities, clinical development, regulatory milestones
and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements
as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy
of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval;
the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug
candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain
and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug
development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional
funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter
into additional collaboration agreements beyond its existing strategic partnerships or collaborations, as well as those risks more fully
discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission.
All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation
to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as may be required by law.
Investor Contacts
Raymond Tam
Raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com